Cardiovascular Systems Inc

Cardiovascular Systems — Q4 FY2019 Earnings Presentation

12 slides from Cardiovascular Systems's earnings presentation, Aug 6, 2019

  1. Slide 1: Q4 FY19 Earnings Call

    Q4 FY19 Earnings Call August 6, 2019

  2. Slide 2: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  3. Slide 3: Q4 CSI Worldwide Revenues of $68.2 Million

    Q4 CSI Worldwide Revenues of $68.2 Million 15% Increase in Revenue $ in millions Revenues US Coronary grew 16% Drivers US Peripheral grew 12% 11% unit growth US Adoption of coronary toolkit Drivers Peripheral, 16% unit growth $48.2 US Coronary, Strong OBL and hospital $17.5 growth International grew

  4. Slide 4: Q4 FY19 Financial Results

    Q4 FY19 Financial Results ($ in millions) Worldwide Peripheral Revenue Worldwide Coronary Revenue $48.3 $45.2 $20.0 $43.1 $44.2 $41.2 $18.2 $16.1 $16.0 $15.0 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Q4 FY18 Q1 FY19 Q2 FY19 Q3 FY19 Q4 FY19 Gross Margin Cash and Marketable Securities 81.7% 81.2% 80.9%

  5. Slide 5: Q4 FY19 Highlights

    Q4 FY19 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenue +15.4% to $68.2M • Revenue results driven by • Revenue results driven by • Sold >22,800 OAS units continued penetration of OBL dedicated coronary sales reps • CMS proposed rules for Gross Margin 80.3% market (

  6. Slide 6: Annual Financial Summary

    Annual Financial Summary Cash and Liquidity $350M shelf registration $123M in cash and marketable securities Recurring cash flow $40M line of credit at June 30, 2019 generated from operations unused and available Revenue Adjusted EBITDA Gross Margin (Millions) (Millions) CAGR = 12% $248 $13 $16 $14

  7. Slide 7: Key Events & Milestones

    Key Events & Milestones FY19A FY20E FY21E Sold 80,650 OAS WIRION acquisition • Hemodynamic support - First in Human International revenue = $7.9M • LIBERTY 360 3-Year Data • International revenue = $15-$17.5M Launched OAS in SE Asia, Europe • Launch OAS in up to 10 new countries • Launch OAS in Cana

  8. Slide 8: WIRION Embolic Protection System Acquisition

    WIRIONTM Embolic Protection System Acquisition • WIRION has CE Mark and FDA clearance as a distal embolic protection filter used to protect a patient’s lower extremities from distal embolization that can occur during PVI • WISE LE showed the device is safe and non-inferior to the pre-specified perfo

  9. Slide 9: FY20 Guidance

    FY20 Guidance For fiscal 2020 ending June 30, 2020, CSI anticipates: • Revenue in a range of $278 million to $283 million • Gross profit margin of 79% to 80%; • Net income (loss) of approximately breakeven*; and • Positive Adjusted EBITDA * Excluding intangible asset amortization and direct expenses

  10. Slide 10: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA

  11. Slide 11: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia

  12. Slide 12: Investor Contact

    NASDAQ: CSII Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2019 Cardiovascular Systems, Inc. Sapphire® and OrbusNeich® are trademarks of OrbusNeic

Cardiovascular Systems — Q4 FY2019 Earnings Presentation on 6ix